C07K 19/00
Hybrid peptides , i.e. peptides covalently bound to nucleic acids, or non-covalently
Official title: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
C07K19/00 (Hybrid peptides , i.e. peptides covalently bound to nucleic acids, or non-covalently) appears on 1,696 US grants and 2,807 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,696
- Published applications
- 2,807
- Assignees
- 1,272
- Inventors
- 5,093
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 2 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 3 | 0 |
| 1991 | 4 | 0 |
| 1992 | 6 | 0 |
| 1993 | 5 | 0 |
| 1994 | 2 | 0 |
| 1995 | 10 | 0 |
| 1996 | 13 | 0 |
| 1997 | 19 | 0 |
| 1998 | 31 | 0 |
| 1999 | 29 | 0 |
| 2000 | 20 | 0 |
| 2001 | 22 | 1 |
| 2002 | 15 | 29 |
| 2003 | 13 | 271 |
| 2004 | 19 | 36 |
| 2005 | 13 | 34 |
| 2006 | 22 | 45 |
| 2007 | 33 | 32 |
| 2008 | 31 | 22 |
| 2009 | 29 | 42 |
| 2010 | 31 | 53 |
| 2011 | 33 | 39 |
| 2012 | 33 | 40 |
| 2013 | 31 | 101 |
| 2014 | 49 | 56 |
| 2015 | 61 | 89 |
| 2016 | 48 | 86 |
| 2017 | 70 | 144 |
| 2018 | 71 | 221 |
| 2019 | 106 | 221 |
| 2020 | 136 | 204 |
| 2021 | 129 | 184 |
| 2022 | 143 | 210 |
| 2023 | 109 | 177 |
| 2024 | 122 | 190 |
| 2025 | 121 | 150 |
| 2026 | 58 | 130 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Fluorescent cross-linked RNase H mutant conjugate, miRNA combination and application thereof22 Sep 2026US 12,742,207 B2Shanghai Miran Biotech Co., Ltd.
- Delivery peptides and methods of using the same15 Sep 2026US 12,735,453 B2B. G. Negev Technologies and Applications Ltd.
- TNFR2 agonists with improved stability15 Sep 2026US 12,735,472 B2Universität Stuttgart
- Anti-CD98hc antibody15 Sep 2026US 12,735,478 B2Osaka University
- Modular platform for molecular conjugation8 Oct 2026US 2026/0306645 A1CamBrixBio Ltd
- Mhc class i molecules8 Oct 2026US 2026/0308228 A1Immudex ApS
- Il12rb2 binding molecules and methods of use8 Oct 2026US 2026/0308265 A1Synthekine, Inc.
- Genetically modified probiotics for oral delivery of renin-angiotensin related therapeutic proteins and peptides1 Oct 2026US 2026/0297153 A1
- High-affinity t cell receptor for identifying kras mutation and use thereof1 Oct 2026US 2026/0297159 A1Xlifesc, Ltd.
Most cited
By later US patents
- Method for making heteromultimeric polypeptides932US 5,731,168 AGenentech, Inc. · 1998
- Methods for producing members of specific binding pairs893US 5,969,108 ACambridge Antibody Technology Limited · 1999
- Binding proteins for recognition of DNA434US 6,007,988 AMedical Research Council · 1999
- Binding proteins for recognition of DNA423US 6,013,453 AMedical Research Council · 2000
- Knobs and holes heteromeric polypeptides342US 7,695,936 B2Genentech, Inc. · 2010